Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 02'nd Aug 2024
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted n
7 Small-Cap Stocks to Buy for Large-Scale Gains
12:25pm, Tuesday, 30'th Jul 2024
Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential.
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
11:06am, Monday, 29'th Jul 2024
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Report Second Quarter 2024 Financial Results on August 5
07:00am, Monday, 22'nd Jul 2024
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on
Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
07:30am, Sunday, 21'st Jul 2024
BioCryst Pharmaceuticals develops complement-mediated and rare disease treatments using a structure-guided drug design process. The company's pipeline also includes promising drug candidates in pivota
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
01:02pm, Thursday, 18'th Jul 2024
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
10:56am, Thursday, 18'th Jul 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 92.6% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the posit
ORLADEYO® (berotralstat) Approved in Peru
07:00am, Tuesday, 09'th Jul 2024
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) i
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Tuesday, 02'nd Jul 2024
RESEARCH TRIANGLE PARK, N.C., July 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted f
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Tuesday, 04'th Jun 2024
RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 1
Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options Additional results from largest body of
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
07:00am, Tuesday, 14'th May 2024
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophyl
ORLADEYO® (berotralstat) Approved in Mexico
07:00am, Monday, 13'th May 2024
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS)
RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotra
BioCryst to Present at Upcoming Investor Conferences
07:00am, Tuesday, 07'th May 2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:
